AC Immune SA (ACIU)

Analysts Issue Forecasts for AC Immune SA's FY2028 Earnings (NASDAQ:ACIU) - Defense World

Defense World

Q3 2024 EPS Estimates for AC Immune SA (NASDAQ:ACIU) Reduced by Analyst - Defense World

Defense World

Leerink Partnrs Weighs in on AC Immune SA's FY2028 Earnings (NASDAQ:ACIU) - MarketBeat

MarketBeat

AC Immune and Takeda Pharma ink $2.1 B deal for immunotherapy to delay Alzheimer's progression - BSA bureau

BSA bureau

AC Immune (ACIU) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Movies UK

Yahoo Movies UK

Equities Analysts Offer Predictions for AC Immune SA's FY2025 Earnings (NASDAQ:ACIU) - Defense World

Defense World

New Forecasts: Here's What Analysts Think The Future Holds For AC Immune SA (NASDAQ:ACIU) - Yahoo New Zealand News

Yahoo New Zealand News

Research Analysts Set Expectations for AC Immune SA's FY2025 Earnings (NASDAQ:ACIU) - MarketBeat

MarketBeat

Top Ranked Momentum Stocks to Buy for January 30th - Yahoo News UK

Yahoo News UK

Takeda agrees to develop active immunotherapy for Alzheimer's - Marketscreener.com

Marketscreener.com

AC Immune's (ACIU) Stock Up Despite Mixed Data From AD Study - Yahoo Movies UK

Yahoo Movies UK

Takeda, AC Immune Ink Exclusive Agreement for Alzheimer's Immunotherapy - Contract Pharma

Contract Pharma

AC Immune (NASDAQ:ACIU) spikes 38% this week, taking one-year gains to 57% - Simply Wall St

Simply Wall St

AC Immune and Takeda ink US$2.1bn biobucks deal - European Biotechnology News

European Biotechnology News

AC Immune's Alzheimer's vaccine draws $2.2B in Takeda deal - BioWorld Online

BioWorld Online

Gold Down Over 1%; AC Immune Shares Spike Higher - AC Immune (NASDAQ:ACIU) - Benzinga

Benzinga

Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday? - AC Immune (NASDAQ:ACIU), - Benzinga

Benzinga

Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday? - Investing.com UK

Investing.com UK

Takeda shells out $100m to license AC Immune's Phase II Alzheimer's therapy - Pharmaceutical Technology

Pharmaceutical Technology

Alzheimer's vaccine licensing deal boosts AC Immune - MSN

MSN

Takeda and AC Immune ink $2.1 billion Alzheimer's therapy deal - Investing.com

Investing.com

AC Immune rockets 47% on Alzheimer's therapy deal with Takeda (NASDAQ:ACIU) - Seeking Alpha

Seeking Alpha

Sizing Up a Micro-Cap Biotech for a Speculative Play - TheStreet

TheStreet

Alzheimer’s vaccine licensing deal boosts AC Immune - MarketWatch

MarketWatch

AC Immune's (ACIU) Share Price Surges Pre-Market - Stocks Telegraph

Stocks Telegraph

AC Immune jumps on licensing deal with Takeda for Alzheimer's disease treatment - XM

XM

Takeda and AC Immune ink $2.1 billion Alzheimer's therapy deal By Investing.com - Investing.com

Investing.com

AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update - Yahoo Finance

Yahoo Finance

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid ... - Manchestertimes

Manchestertimes

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid ... - Business Wire

Business Wire

AC Immune (ACIU) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Movies Canada

Yahoo Movies Canada

AC Immune (ACIU) Surges 43% in the Past 3 Months: Here's Why - Yahoo Singapore News

Yahoo Singapore News

AC Immune (NASDAQ:ACIU) Stock Rating Upgraded by StockNews.com - MarketBeat

MarketBeat

AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Singapore News

Yahoo Singapore News

AC Immune (ACIU) Reports Q1 Loss, Misses Revenue Estimates - Yahoo New Zealand News

Yahoo New Zealand News

AC Immune SA (NASDAQ:ACIU) Short Interest Update - Defense World

Defense World

AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet - Simply Wall St

Simply Wall St

We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth - Simply Wall St

Simply Wall St

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

GlobeNewswire Inc.

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update - Yahoo Finance

Yahoo Finance

ACI-19764 is a potent brain-penetrant NLRP3 inhibitor for neurological disorders - BioWorld Online

BioWorld Online

AD/PD 2024: AC Immune looks to second part of Phase II Parkinson's vaccine trial - Clinical Trials Arena

Clinical Trials Arena

AC Immune Announces Upcoming Presentations at AD/PD™ 2024 - Yahoo Finance

Yahoo Finance

AbbVie (ABBV) Announces Appointment of New CEO Robert Michael

Zacks Investment Research

5 Little-Known Penny Stocks With Massive Upside Potential - Insider Monkey

Insider Monkey

Pfizer's (PFE) Ulcerative Colitis Pill Velsipity Gets EU Nod

Zacks Investment Research

Down -35.7% in 4 Weeks, Here's Why AC Immune (ACIU) Looks Ripe for a Turnaround

Zacks Investment Research

Roche jumps ship on AC Immune - European Biotechnology News

European Biotechnology News

AC Immune stock slips as Roche ends Alzheimer's deal (NASDAQ:ACIU) - Seeking Alpha

Seeking Alpha

AC Immune (ACIU) is a Great Momentum Stock: Should You Buy?

Zacks Investment Research